Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.47 |
| ▸ | F2 | P00734 | 5/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032691 | 0.88 | F10 (0.43) | F10F2KLK1 | |
| SCHEMBL5035147 | 0.83 | F10 (0.43) | F10F2 | |
| SCHEMBL4605304 | 0.80 | F10 (0.50) | F10F2KLK1 | |
| SCHEMBL4607789 | 0.80 | F10 (0.49) | F10F2KLK1 | |
| SCHEMBL4605394 | 0.79 | F10 (0.50) | F10F2KLK1 | |
| SCHEMBL4412919 | 0.79 | F10 (0.65) | F10F2 | |
| SCHEMBL5039447 | 0.78 | F10 (0.44) | F10F2 | |
| SCHEMBL2783021 | 0.77 | F10 (0.49) | F10F2 | |
| SCHEMBL2781282 | 0.77 | F10 (0.51) | F10F2KLK1 | |
| SCHEMBL2780778 | 0.77 | F10 (0.50) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628971-B1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-07 | — | — | EP | claimed |
| US-7223780-B2 | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | claimed |
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | claimed |
| EP-1479679-A1 | Triazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1628971-B1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7223780-B2 | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1628971-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101555-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479679-A1 | Triazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | TFPI, F11, TFPI2 | F10 21/4885F2 4/4885KLK1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.